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Study objectives: This study was conducted to describe the different antibiotics that are used 
in the home management of chronic obstructive pulmonary disease (COPD) exacerbations and 
to estimate the failure rates following the initiation of the antibiotic.
Methods: A cohort study was conducted. Patients enrolled in a COPD home management 
program were included in the analysis. Failure rates were deﬁ  ned as an additional prescription 
of an antibiotic, an emergency room visit, or a hospitalization for a COPD exacerbation in the 
30 days following the initiation of the antibiotic.
Results: A total of 1180 episodes of antibiotic treatment were analyzed. Overall, 348 episodes 
led to a failure (29.5%). The most frequently used antibiotics were cefuroxime (45.9%) and 
ciproﬂ  oxacin (21.1%).
Conclusion: This project demonstrates that a wide range of antibiotics were prescribed to our 
population of COPD patients with a moderate to severe form of the disease. Many treatment 
failures (about 30%) occurred in the 30-day period following the initiation of the home therapy 
with an antibiotic. Clinicians should be aware of this high failure rate when managing mild 
exacerbations of COPD at home.
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Introduction
Several trials have demonstrated that antibiotics are beneﬁ  cial over placebo for the 
treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD) 
(Anthonisen et al 1987; Saint et al 1995; Ram et al 2006). COPD guidelines recom-
mend the use of antibiotics when clinical signs of infection are apparent; for example, 
increased sputum volume and purulence, and/or fever (GOLD 2007). Antimicrobial 
choices can be based upon the local patterns of antibiotic sensitivity among the 
most common responsible pathogens (GOLD 2007). Canadian guidelines recom-
mend the use of amoxicillin, doxycycline, trimethoprim/sulfamethoxazole, second 
or third-generation cephalosporins, or extended spectrum macrolides in the absence 
of risk factors, whereas ﬂ  uoroquinolones or beta-lactam/beta-lactamase inhibitor 
(amoxicillin/clavulanic acid) are suggested for patients who have an forced expiratory 
volume in one second (FEV1) lower than 50% of the predicted, four or more COPD 
exacerbations per year, ischemic heart disease, home oxygen use, chronic use of oral 
corticosteroids, and/or antibiotherapy taken in the previous three months (O’Donnell 
et al 2007). The authors do however, specify that this is a level 3c recommendation 
(“consensus from expert groups based on clinical experience and poor evidence to 
support a recommendation for or against use”). Furthermore, it is also speciﬁ  ed that 
antibiotics for patients with no risk factors when combined with prednisone may suf-
ﬁ  ce (O’Donnell et al 2007).
Most patients included in our COPD home management program have the risk 
factors associated with the use of second line antimicrobial agents (ie, for patients with International Journal of COPD 2008:3(2) 320
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risk factors), speciﬁ  ed in the Canadian COPD guidelines, 
but various antibiotics, including ﬁ  rst-line agents, are used. 
Therefore, we sought to describe the type of antibiotics that 
are used by COPD patients included in our home manage-
ment program and to estimate the failure rate associated 
with this therapy.
Methods
We conducted a retrospective cohort study to describe the 
different antibiotics that are used for COPD patients included 
in our home management program, and estimate the treat-
ment failure rates. All patients participating in the COPD 
home-management program of l’Hôpital du Sacré-Coeur de 
Montréal (HSCM) were included in the analysis if they had 
follow-up data for at least 12 months. This program follows 
patients for whom COPD represents a chronic disease that 
has an important impact on their quality of life and who are at 
risk of severe exacerbations; for example, have had previous 
exacerbations requiring acute care. Patient charts updated 
at least every month by doctors, nurses, and pharmacists 
were used for data collection. Cohort entry corresponded 
to inclusion in the program (started in 1995) and follow-up 
until exclusion from the program, death, or November 31st, 
2004, whichever occurred ﬁ  rst. Antibiotics were initiated at 
home for these patients when they reported at least two of 
the following criteria: dyspnea, increased sputum produc-
tion, increased sputum volume (Anthonisen et al 1987). The 
selection of an appropriate antibiotic for the patient’s action 
plan is at the physician’s discretion and is not based upon 
prespeciﬁ  ed criteria with the exception of drug allergy or 
intolerance. Usually, the action plan (antibiotic) is prescribed 
for a year and rotation from one antibiotic to another over 
the course of the year to treat subsequent exacerbations is 
not done unless treatment fails. Microbiologic data is not 
usually available to select the antibiotic; patients who begin 
an exacerbation are managed by telephone communication 
between the nurse and the patient. Usual treatment duration 
is of 10 days (with the exception of azithromycin which in 
most cases is prescribed for 5 days). An intravenous antibi-
otic regimen and a concomitant use of two antibiotics were 
excluded from the analysis, since these cases are managed 
differently (usual protocol is not followed for these cases at 
our program). Patients included in this program are followed 
by one of the respiratory physicians at HSCM with meetings 
once or twice a year at the outpatient clinic.
Data collected included antibiotic treatments (number 
and agents used), number of emergency room visits for 
a COPD exacerbation, number of hospitalizations for a 
COPD exacerbation, use of oral and inhaled corticosteroids, 
use of bronchodilators (inhaled short and long-acting 
bronchodilators, theophylline), FEV1, level of dyspnea 
(based on the cardiac rhythm management dyspnea index; 
scale 1–5, a higher score implies a higher level of dyspnea), 
co-morbidities, age, sex, smoking status, home oxygen use, 
hypercapnia, and level of autonomy (scale 1–6, a higher score 
implies a better level of autonomy).
The main outcome was the type of antimicrobial agents 
prescribed to the patients in the cohort. The secondary 
outcome was treatment failure in the 30 days following the 
initiation of the antibiotic. Treatment failure was considered 
if one of the following events occurred in the 30-day period 
following the initiation of the antibiotic: prescription of 
the same antibiotic for home management once the initial 
treatment has been completed; use of a different antimicro-
bial agent for home management of a COPD exacerbation 
(change in the antibiotic initially prescribed before treatment 
completion or upon treatment completion); emergency room 
visit for a COPD exacerbation (as soon as 1 day following 
treatment initiation); and hospitalization for a COPD exac-
erbation (as soon as 1 day following treatment initiation). 
These were described separately and then, treatment failure 
was assessed based on the occurrence of one of these four 
events; if more than one occurred in the 30-day period, only 
one treatment failure was calculated. Furthermore, a delay 
of at least 30 days between two exacerbations in the same 
patient was mandatory to consider the occurrence of a new 
COPD exacerbation requiring antibiotic therapy. The con-
duct of this project was approved by the ethics committee 
of our institution.
Statistical analysis
Descriptive statistics – proportions and standard deviation – 
were calculated to describe the type of antibiotics 
prescribed.
Results
The initial cohort included 2288 episodes of oral antibiotic 
treatments received by 152 COPD patients included in the 
home management program between 1995 and 2004. We 
excluded 972 antibiotic treatments that were preceded in the 
30 days by a COPD exacerbation (hospitalization, emergency 
room visit, another antibiotic therapy), and 136 episodes 
for which complete clinical data of the patients were not 
available. Therefore, a total of 1180 episodes of antibiotic 
treatment received by 152 patients were analyzed. The dis-
tribution of the characteristics of the patients at cohort entry International Journal of COPD 2008:3(2) 321
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and antibiotic choices are found in Table 1 and Table 2. All 
patients included in our cohort had an FEV1 lower than 50% 
at cohort entry, and therefore were in the category “with 
risk factors” based on the Canadian guidelines. The most 
frequently used antibiotics were cefuroxime (45.9%) and 
ciproﬂ  oxacin (21.1%). A total 473 of the 1180 antibiotic 
treatments (40.0%) were combined with prednisone.
Overall, 348 of the 1180 episodes led to a treatment fail-
ure (29.5%), including 103 hospitalizations for a COPD exac-
erbation, 29 emergency room visits, 44 repeated treatments 
with the same antibiotic, and 172 repeated treatments with 
a different antibiotic (Table 3). The average time between 
the initiation of the antibiotic and the treatment failure was 
15.3 days (median of 14 days).
A total of 418 of the 1180 treatments prescribed (35.4%) 
were antibiotics recommended for patients with risk factors 
according to the Canadian COPD guidelines (ie, amoxicil-
lin/clavulanic acid or ﬂ  uroquinolones). The failure rates 
associated with the use of an antibiotic for patients with risk 
factors was of 32.8% while it was of 27.7% for antibiotics 
in the category of patients without risk factors. The risk of 
having a treatment failure was slightly higher when an anti-
biotic for patients with risk factors was prescribed (data not 
shown, available upon request).
Discussion
Overall, our failure rate was greater than the ones reported 
in the literature that vary from 12% to 21% (Adams et al 
2000; Dewan et al 2000; Miravitlles et al 2001). Potential 
explanations for this difference are our study’s inclusion of 
patients with a more severe form of the disease, and the use 
of a different deﬁ  nition of failure (Adams et al 2000; Dewan 
et al 2000; Miravitlles et al 2001). Furthermore, about 65% 
of patients received an antibiotic for patients with no risk 
factors, while they were considered at risk based on their 
characteristics (such as FEV1). A deﬁ  ciency in guideline 
conformity and under use with regard to COPD treatment has 
been previously reported (Jans et al 1998; Roche et al 2001; 
Choi et al 2004; Brand et al 2005; Fritsch et al 2005; Boulet 
et al 2006; Glaab et al 2006a, 2006b). However, antibiotic 
treatment recommendations in the Canadian COPD guide-
lines are not based on a high level of evidence.
The main strength of our study is that we collected 
data from a real clinical setting. But our results cannot be 
generalized to all COPD patients since the patients included 
Table 1 Characteristics of the patients at their entry in the COPD 
home management program
Characteristics (n = 152)  N (%)
Gender: Male  76 (50.0)
Mean age: 
49–64 years old  31 (20.4)
65–74 years old  60 (39.5)
75 years old  61 (40.1)
BMI: 
20 37  (24.3)
20–29 92  (60.5)
30 23  (15.1)
Smoking status: 
Past history of smoking  120 (79.0)
Smoker 26  (17.1)
No history of smoking  6 (4.0)
Number of co-morbiditites: 
2 88  (57.9)
2 64  (42.1)
Dyspnea index (scale of 1-5) 
1–2 19  (12.5)
3 29  (19.1)
4–5 104  (68.4)
Level of autonomy (scale 1–6) 
1–3 78  (55.3)
4–6 63  (44.7)
Home oxygen  70 (46.4)
Use of a short-acting bronchodilator   152 (100)
(albuterol and ipratropium)
Use of a long-acting beta-2 agonist  87 (57.2)
Use of an inhaled corticosteroid  132 (86.8)
Use of theophylline  56 (36.8)
Continuous use of oral corticosteroids  22 (14.6)
FEV1 Mean  (± SD)
  32.3% predicted (±9.1)
Annual rate of exacerbations  2.9 (±2.3)
Notes: The mean number of pack-years of smoking was unknown; Based on the CRM 
dyspnea index: a higher score implies a higher level of dyspnea; Questionnaire developed 
for our program (not validated): a higher score implies a better level of autonomy.   The 
six-minute walk distance is unknown.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in one second; 
SD, standard deviation.
Table 2 Antibiotics used to treat acute exacerbations of COPD 
at home
Antibiotics used (n = 1180 treatments)  N (%)
Cefuroxime 542  (45.9)
Ciproﬂ  oxacin  249 (21.1)
Levoﬂ  oxacin  73 (6.2)
Azithromycin 56  (4.8)
Amoxicillin 49  (4.2)
Moxiﬂ  oxacin  48 (4.1)
Trimethoprim-sulfamethoxazole 41  (3.5)
Gatiﬂ  oxacin  24 (2.0)
Amoxicillin-clavulanic acid  20 (1.7)
Others (ampicillin, cephalexin, cefaclor, ceﬁ  xime,  37 (3.1)
cefprozil, clindamycin, cloxacillin,
erythromycin, oﬂ  oxacin, penicillin,
pivampicillin, trovaﬂ  oxacin) International Journal of COPD 2008:3(2) 322
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in our program have a severe form of the disease. We 
attempted to compare failure rates between different classes 
of antibiotic (data not shown) by performing a Chi-square test 
and a Poisson regression analysis, but our study design had 
many limitations such as lack of power and the absence of 
randomization. In fact, patients who received large spectrum 
antibiotics had a higher risk of failure even after adjusting our 
results for confounding variables. This suggests that patients 
who received large spectrum of antibiotics were the ones with 
the most severe disease (ie, higher risk of failure) and we could 
not completely exclude the possibility of residual confounding 
of disease severity in the analysis of our results.
In conclusion, a wide range of antibiotics are prescribed 
to our patients with moderate to severe COPD to treat mild 
exacerbations at home. Overall, the initiation at home of 
an antibiotic for an acute exacerbation of COPD failed to 
prevent the use of another antibiotic treatment, an emergency 
room visit, or a hospitalization in 30% of the cases. Results 
of this study should alert the clinician to the high risk of 
treatment failure when managing mild exacerbations of 
COPD at home in patients with severe disease. Furthermore, 
our results support the implementation of strategies to better 
promote the application of clinical practice guidelines for the 
management of chronic diseases.
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Table 3 Description of treatment failure (N = 348 failures for 1180 
episodes of treatment)
Type of failure  N (%)
Emergency room visit  29 (8.3)
Hospitalization 100  (28.7)
Re-prescription of the same antibiotic  44 (12.6)
Re-prescription of the same antibiotic followed  1 (0.3)
by a hospitalization 
Prescription of a different antibiotic  172 (49.4)
Prescription of a different antibiotic followed  2 (0.6)
by a hospitalization